Latest Results for Anti-Angiogenic Drugs in Cancer Treatment

Author(s): Sofie Frandsen, Sascha Kopp, Markus Wehland, Jessica Pietsch, Manfred Infanger, Daniela Grimm

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 39 , 2016

Become EABM
Become Reviewer
Call for Editor


Background: Angiogenesis is a mechanism, which tumors use to recruit oxygen and nutrients in order to maintain growth. The vascular endothelial growth factor family is the primary mediator of this process. For the last couple of decades, inhibition of angiogenesis has been the subject of extensive research, but so far anti-angiogenic drugs have only shown a modest effect.

Methods: This paper reviews four relevant anti-angiogenic drugs: bevacizumab, ramucirumab, nintedanib and sunitinib. The primary focus will be recent trials investigating the effects of the drugs in lung, breast and gastrointestinal cancers. Furthermore, there will be a discussion of unsolved problems, such as lack of biomarkers, drug resistance, and adverse events, for which a solution is necessary in order to improve the benefit of anti-angiogenic drugs in the future.

Results: Anti-angiogenic therapy is extensively used in the treatment of cancer. There is evidence that drug-induced hypertension serves as a biomarker for a good response to therapy. Currently several possible anti-angiogenic biomarkers are under discussion. Further examples are changes in VEGF or interleukin (IL)-8 polymorphisms, changed plasma levels of VEGF, or tumor microvessel density. To overcome therapyassociated problems, more research for valid biomarkers is necessary. In addition, a strategy to overcome resistance problems and severe adverse events is desirable.

Conclusion: Clinical trials evaluating targeted therapies with specificity for resistance mechanisms are necessary. Moreover, biomarker studies in future clinical investigations are important for the development of the next generation of anti-angiogenic drugs.

Keywords: Cancer, angiogenesis, tyrosine kinase inhibitors, bevacizumab, ramucirumab, nintedanib, sunitinib.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 13 December, 2016
Page: [5927 - 5942]
Pages: 16
DOI: 10.2174/1381612822666160715130419
Price: $65

Article Metrics

PDF: 57